XOSPATA: payments to doctors
Payments that named XOSPATA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.7M
- Providers
- 5,683
- Transactions
- 15,404
- Average per transaction
- $177
The per-transaction average — $177 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,683 providers the average total is $480, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $2,094,728 | 76.8% |
| Astellas Pharma Global Development | $444,523 | 16.3% |
| Astellas Pharma Inc | $140,121 | 5.1% |
| Astellas Pharma Europe Ltd | $46,965 | 1.7% |
| Astellas US LLC | $107 | 0.0% |